Apricus Biosciences (APRI) to File for Market Authorization to Sell Vitaros(R) for Erectile Dysfunction in Latin America
8/8/2011 9:40:43 AM
SAN DIEGO, Aug. 8, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (Nasdaq:APRI) announced today that it will file for market authorization to sell its erectile dysfunction drug, Vitaros®, in Latin America. The Company also stated that it has engaged the services of Quintiles Global Regulatory Affairs, a leading international regulatory consultancy, to prepare its regulatory filings for Vitaros® for marketing approval in the following Latin American countries: Mexico, Brazil, Argentina, Colombia, Chile and Peru. "By preparing to file in Latin America, we are moving forward with our plan to make Vitaros® available worldwide," noted Dr. Bassam Damaj, Chairman, President and Chief Executive Officer of Apricus Bio.